Search

Your search keyword '"Schuitemaker, Hanneke"' showing total 1,106 results

Search Constraints

Start Over You searched for: Author "Schuitemaker, Hanneke" Remove constraint Author: "Schuitemaker, Hanneke"
1,106 results on '"Schuitemaker, Hanneke"'

Search Results

1. Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy

2. CoPoP liposomes displaying stabilized clade C HIV-1 Env elicit tier 2 multiclade neutralization in rabbits

3. Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial.

4. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.

6. Mosaic vaccine-induced antibody-dependent cellular phagocytosis associated with delayed HIV-1 viral load rebound post treatment interruption

7. Enhancing breadth and durability of humoral immune responses in non-human primates with an adjuvanted group 1 influenza hemagglutinin stem antigen

8. Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models

9. Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques

10. Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2

11. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

12. Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola

13. Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques

14. Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques

17. Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters

18. Impact of SARS-CoV-2 spike stability and RBD exposure on antigenicity and immunogenicity

19. Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques

20. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

21. Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study

22. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17–22)

23. Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters

24. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

25. SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques

26. Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease

27. Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption

28. Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans

29. First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector

31. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.

33. Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate

34. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses

36. Inactivated Viral Vaccines

37. Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load

38. Publisher Correction: Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

41. Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer

42. Booster immunization with Ad26.COV2.S or Omicron adapted vaccine enhanced immune responses and efficacy against SARS-CoV-2 Omicron in non-human primates

43. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys

44. Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys

46. Combination Ad26.RSV.preF/RSV preF protein vaccine induces superior humoral, cellular, and protective immunity compared with individual vaccine components in preclinical models

47. Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels

48. Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials

50. Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV‐1 positive patients with well‐estimated dates of seroconversion

Catalog

Books, media, physical & digital resources